Engineered cpl-1 endolysin for dual-action treatment of central nervous system bacterial infections: killing antibiotic-resistant bacteria and neutralizing released toxins
Abstract The global rise of antimicrobial resistance and the limited efficacy of current therapies against toxin-mediated pathology highlight the urgent need for innovative anti-infective strategies. In pneumococcal meningitis, a leading cause of mortality and long-term neurological sequelae, treatment is complicated not only by antibiotic-resistant Streptococcus pneumoniae (the pneumococcus) but also by the release of pneumolysin (Ply), a pore-forming toxin that drives neuronal damage and neuroinflammation. Here, we present the design and preclinical characterization of an endolysin-based dual-action fusion protein, using cpl-1 as a proof-of-concept scaffold, that combines bactericidal activity with toxin-neutralizing properties for infectious disease treatment. We engineered a chimeric protein by fusing a Mannose Receptor C-type 1 (MRC-1)-derived anti-Ply peptide to the N-terminus of the well-characterized pneumococcal endolysin cpl-1. The engineered endolysin demonstrated potent bactericidal activity against a broad panel of pneumococcal strains, including antibiotic-resistant and non-vaccine serotypes, producing an approximately 2-log10 CFU/mL reduction in human blood and approximately 60% reduction in turbidity in human cerebrospinal fluid. Importantly, the fusion protein could bind Ply reducing infection-associated neuronal cytotoxicity by more than 25% compared with cpl-1 in human neuronal cell models, addressing a key limitation of conventional bactericidal antibiotic therapies which can exacerbate toxin release. Mechanistically, incorporation of the MRC-1-derived peptide reduced toxin-induced damage, enabling simultaneous bacterial clearance and toxin neutralization. Furthermore, the fusion protein also demonstrated the ability to cross the blood-brain barrier in vivo; in a mouse model of penicillin-resistant invasive pneumococcal disease, the combination treatment, thanks to Ply-binding peptide (PBP)-cpl-1’s synergy with standard-of-care antibiotics, resulted in approximately 60% survival following a single dose and 65% survival following two doses, compared with 0% survival in untreated controls, together with delayed disease progression and reduced inflammatory responses in the brain and peripheral tissues. Collectively, our findings position engineered endolysins as a promising next-generation anti-infective strategy for the treatment of severe infections, particularly in anatomically protected sites such as the central nervous system, where current antibiotic therapies often show limited efficacy.
Authors
- Adit B. Alreja (ORCID: https://orcid.org/0000-0003-3607-8005)
- Daniel Kemboi (ORCID: https://orcid.org/0000-0002-0541-4064)
- Niels Vander Elst (ORCID: https://orcid.org/0000-0001-6289-7288)
- Federico Iovino (ORCID: https://orcid.org/0000-0001-5249-9120)
- Kristine Farmen (ORCID: https://orcid.org/0000-0002-3004-7462)
- Daniel C Nelson (ORCID: https://orcid.org/0000-0003-3248-4831)
- Lotte Merlijn
- Valentina Mocci
- Clara Caceffo
Publication Details
- Journal
- Molecular Medicine
- Published
- 2026-11-14
- DOI
- https://doi.org/10.1186/s10020-026-01697-w
- Primary Topic
- Bacteriophages and microbial interactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00